Results 91 to 100 of about 5,417,325 (244)

Diuretic Resistance

open access: yes, 2017
Diuretic resistance is defined as a failure to achieve the therapeutically desired reduction in edema despite a full dose of diuretic. The causes of diuretic resistance include poor adherence to drug therapy or dietary sodium restriction, pharmacokinetic
Ellison, D.H. (David)   +3 more
core   +1 more source

Diuretic and anti-diuretic bioactivity differences of the seed and shell extracts of Alpinia oxyphylla fruit [PDF]

open access: yes, 2016
Background: Alpinia oxyphylla fruit (AOF, Yizhi in Chinese) is a well-known traditional Chinese medicine as an anti-diuretic agent and composed of two parts i.e. seed and shell.
Yonghui Li   +8 more
core   +1 more source

Growth differentiation factor‐15 and N‐terminal pro‐BNP in acute heart failure with preserved ejection fraction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki   +11 more
wiley   +1 more source

The role of intra‐abdominal pressure and point of care ultrasound to guide decongestive therapies in acute heart failure

open access: yesESC Heart Failure
Aims Effective decongestion is crucial in managing acute decompensated heart failure (ADHF). Persistent congestion post‐diuretic therapy correlates with adverse outcomes.
C. Josa‐Laorden   +20 more
doaj   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro   +15 more
wiley   +1 more source

First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery

open access: yesBMC Pediatrics, 2019
Background Postoperative fluid management in critically ill neonates and infants with capillary leak syndrome (CLS) and extensive volume overload after cardiac surgery on cardiopulmonary bypass is challenging.
Anne Kerling   +7 more
doaj   +1 more source

Pharmacokinetics of torasemide and its metabolites in end-stage renal disease [PDF]

open access: yes, 1994
The pharmacokinetics of torasemide, a new loop diuretic, as well as its active metabolites M1 and M3, and its inactive main metabolite, M5, were studied in 12 patients with end-stage renal failure during single i.v.
Schwab, A.   +5 more
core   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo   +7 more
wiley   +1 more source

Continuous Versus Intermittent Loop Diuretics Step‐by‐Step Protocol in Acute Heart Failure (DIUR‐AHF): A Propensity‐Matched Analysis

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Loop diuretics are used to solve congestion in acute heart failure. However, a clear indication about the best infusion modality, dose, and duration of the treatment has not yet been established.
Gaetano Ruocco   +16 more
doaj   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy